TRCT
INDP icon

Tower Research Capital (TRC)’s Indaptus Therapeutics INDP Stock Holding History

Tower Research Capital (TRC)’s Portfolio INDP Stock Details INDP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.44K Sell
1,890
-1,261
-40% -$2.7K ﹤0.01% 4315
2025
Q4 		$9.17K Buy
3,151
+2,678
+566% +$7.6K ﹤0.01% 3917
2025
Q3 		$1.36K Buy
473
+365
+338% +$2.63K ﹤0.01% 4812
2025
Q2 		$1.14K Sell
108
-17
-14% -$198 ﹤0.01% 4869
2025
Q1 		$1.92K Hold
125
– – ﹤0.01% 4626
2024
Q4 		$2.96K Sell
125
-47
-27% -$1.49K ﹤0.01% 4741
2024
Q3 		$5.97K Buy
172
+25
+17% +$1.23K ﹤0.01% 4198
2024
Q2 		$8.7K Buy
147
+2
+1% +$133 ﹤0.01% 4314
2024
Q1 		$9.11K Sell
145
-23
-14% -$1.23K ﹤0.01% 3895
2023
Q4 		$8.27K Buy
168
+60
+56% +$3.77K ﹤0.01% 4526
2023
Q3 		$8.36K Sell
108
-94
-47% -$6.35K ﹤0.01% 4358
2023
Q2 		$10.8K Sell
202
-17
-8% -$992 ﹤0.01% 4058
2023
Q1 		$11K Sell
219
-22
-9% -$1.04K ﹤0.01% 4224
2022
Q4 		$10K Buy
241
+229
+1,908% +$11.6K ﹤0.01% 4015
2022
Q3 		$1K Sell
12
-49
-80% -$3.82K ﹤0.01% 5792
2022
Q2 		$4K Buy
+61
New +$4.76K ﹤0.01% 5218
2019
Q3 		– Sell
-3
Closed -$26K – 4292
2019
Q2 		$26K Buy
+3
New +$37.8K ﹤0.01% 2003
2019
Q1 		– Hold
0
– – – 3291
2018
Q4 		– Hold
0
– – – 2798
2018
Q3 		– Hold
0
– – – 3595
2016
Q2 		– Hold
0
– -$3K – 4678
2016
Q1 		– Hold
0
– – – 3105

Other funds holding INDP

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return
Carson Wealth (CWM LLC)
Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return

Tower Research Capital (TRC)'s INDP Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its Indaptus Therapeutics (INDP) stake by 40% in Q1 2026, selling an estimated $2.7K and leaving 1,890 shares worth $3.44K. The position accounts for ﹤0.01% of the portfolio, ranked #4315.

Tower Research Capital (TRC) first reported a position in INDP in Q2 2019 and has held it in 17 quarters since. The position peaked at $26K in Q2 2019. 6 funds tracked by Wall St. Rank hold INDP as of Q1 2026.

  • Tower Research Capital (TRC) held 1,890 shares of Indaptus Therapeutics worth $3.44K as of Q1 2026.
  • Tower Research Capital (TRC) sold 1,261 Indaptus Therapeutics shares in Q1 2026, an estimated $2.7K.
  • Indaptus Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #4315 holding.
  • Tower Research Capital (TRC) first reported a position in Indaptus Therapeutics in Q2 2019 and has held it in 17 quarters since.
  • Tower Research Capital (TRC)'s Indaptus Therapeutics position peaked at $26K in Q2 2019.
  • 6 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.